Can estrogen cream help with urinary tract inflammation?
Locally applied oestrogen cream demonstrably reduces the risk of recurrent urinary tract infections in women after the menopause. Oestrogen pills do not help with this; discuss the cream with your doctor if you regularly suffer from bladder infections.
After the menopause, oestrogen levels drop, and this has a direct impact on the lining of the bladder and the vagina. The tissue becomes thinner and drier, acidity rises, and protective bacteria (such as Lactobacilli) partially disappear. As a result, disease-causing bacteria can gain a foothold more easily, and the risk of recurrent urinary tract infections increases.
Locally applied oestrogen cream can reduce that risk considerably. Five studies involving a total of 1936 women show that the number of recurrent infections falls by approximately 58% compared with placebo. That is a clear and consistent effect. The cream also lowers vaginal acidity, which is likely one of the explanations: a lower pH makes the environment less favourable for harmful bacteria.
Higher weekly doses of 850 micrograms or more appear, in the available studies, to lead to better protection, with 51 to 100% of women remaining infection-free during follow-up. No certainty exists yet about the ideal dose, as this relationship has only been examined in a limited number of studies.
Oral oestrogen pills do not work for this problem. Three studies involving 2766 women found no difference compared with placebo. It therefore appears that the effect must occur locally: via the cream directly on the mucous membrane, not through the bloodstream.
Side effects of the cream, such as irritation, itching or a burning sensation, are reported, but in the studies they did not occur significantly more often than with placebo. Serious complaints appear to be rare. If you have doubts about whether the cream suits you, discuss this with your general practitioner or gynaecologist.
This answer is based on a meta-analysis of five studies with 1936 participants for the local cream, and three studies with 2766 participants for the oral variant. The researchers rated the evidence as reasonably strong for the primary outcome (risk reduction of recurrent infections), but as thin for dosage and side effects. The mechanism via vaginal pH is supported by only two studies.